Roche and Bayer are expanding their companion Dx collaboration; Quest Diagnostics snatched up Summit Health;

> Roche ($RHHBY) and Bayer have expanded their companion diagnostics collaboration into multiple projects. Story

> Harvard Medical School and Columbia University won grants of about $12.3 million this year from the National Institute of Allergy and Infectious Diseases to develop translational research centers focused on molecular diagnostics technologies. Story (reg. req)

> Exosome Diagnostics raised a $27 million Series B round, led by Qiagen ($QGEN) and Arcus Ventures, to help propel its prostate cancer urine test to market. Story

> Seattle's Pacific Biomarkers will use its biomarker assays in a collaboration deal with Shanghai's WuXi PharmaTech ($WX) focused on the development of new treatments. Release

> Quest Diagnostics ($DGX) said it will buy Summit Health, an Arizona company that provides finger-stick diagnostics and other biometric screenings. Financial terms were not disclosed. Release

> NeuroMetrix ($NURO) plans to seek regulatory approval in Japan for its point-of-care test to detect diabetic peripheral neuropathy. Release

Suggested Articles

The FDA granted an expanded indication to GT Medical’s GammaTile cancer therapy, broadening its use to newly diagnosed brain cancer patients.

A new company focusing on sperm rather than egg biology debuted with goals of increasing fertility rates and reducing pregnancy complications.

Verily has obtained a second agency green light for measuring irregular heartbeats using its prescription smartwatch.